METHODOLOGY FOR EVALUATING MEANINGFUL CHANGE THRESHOLDS IN PATIENT-REPORTED OUTCOME (PRO) MEASURES FOR CORNEAL EVENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) RECEIVING SINGLE-AGENT BELANTAMAB MAFODOTIN (BELAMAF)

被引：0
|
作者：
Eliason, L. [1 ]
Loubert, A. [2 ]
Gorsh, B. [1 ]
Meunier, J. [2 ]
Kleinman, D. [3 ]
Sapra, S. [1 ]
Regnault, A. [2 ]
机构：
[1] GlaxoSmithKline, Upper Providence, PA USA
[2] Modus Outcomes, Lyon, France
[3] Univ Rochester, Flaum Eye Inst, Rochester, NY USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN309
引用
收藏
页码：S477 / S477
页数：1
相关论文
共 46 条
  • [1] DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Popat, Rakesh
    Lonial, Sagar
    Voorhees, Peter M.
    Degli Esposti, Simona
    Gupta, Ira
    Opalinska, Joanna
    Sapra, Sandhya
    Gorsh, Boris
    He, Zangdong
    Kleinman, David M.
    Schaumberg, Debra
    Loubert, Angely
    Meunier, Juliette
    Regnault, Antoine
    Eliason, Laurie
    BLOOD, 2020, 136
  • [2] Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)
    Popat, Rakesh
    Kazantzi, Aikaterini
    Kleinman, David
    Lichenstein, Carolyn
    Paka, Prani
    Salter, John
    Byrne, Julie
    Doherty, Allison
    Degli Esposti, Simona
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S30 - S30
  • [3] Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
    Lonial, Sagar
    Nooka, Ajay K.
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Potter, Heather A.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Byrne, Julie
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Gupta, Ira
    Dana, Reza
    Farooq, Asim V.
    Colby, Kathryn
    Jakubowiak, Andrzej
    BLOOD CANCER JOURNAL, 2021, 11 (05)
  • [4] Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
    Sagar Lonial
    Ajay K. Nooka
    Praneetha Thulasi
    Ashraf Z. Badros
    Bennie H. Jeng
    Natalie S. Callander
    Heather A. Potter
    Douglas Sborov
    Brian E. Zaugg
    Rakesh Popat
    Simona Degli Esposti
    Julie Byrne
    Joanna Opalinska
    January Baron
    Trisha Piontek
    Ira Gupta
    Reza Dana
    Asim V. Farooq
    Kathryn Colby
    Andrzej Jakubowiak
    Blood Cancer Journal, 11
  • [5] Patient-Reported Experiences during and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study
    Eliason, Laurie
    Correll, Julia
    Martin, Mona
    Cardellino, Anna
    Opalinska, Joanna
    Piontek, Trisha
    Gorsh, Boris
    Sapra, Sandhya
    Popat, Rakesh
    BLOOD, 2020, 136
  • [6] DREAMM-2: Single-agent belantamab mafodotin (belamaf; GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) - outcomes by prior therapies
    Weisel, K.
    Lonial, S.
    Lee, H.
    Badros, A.
    Trudel, S.
    Nooka, A.
    Chari, A.
    Abdallah, A-O
    Callander, N.
    Sborov, D.
    Suvannasankha, A.
    Vorhees, P.
    Opalinska, J.
    Hoos, A.
    Zhi, E.
    Baron, J.
    Piontek, T.
    Jewell, R.
    Gupta, I
    Cohen, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 109 - 110
  • [7] Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Nooka, Ajay
    Lee, Hans C.
    Badros, Ashraf Z.
    Voorhees, Peter
    Hultcrantz, Malin
    Karlin, Lionel
    Arnulf, Bertrand
    Richardson, Paul G.
    Zhi, Eric
    Baron, January
    Piontek, Trisha
    Lewis, Eric
    Opalinska, Joanna
    Gupta, Ira
    Cohen, Adam D.
    Lonial, Sagar
    BLOOD, 2020, 136
  • [8] Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Lonial, Sagar
    Nooka, Ajay
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Byrne, Julie
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Gupta, Ira
    Dana, Reza
    Farooq, Asim
    Jakubowiak, Andrzej
    BLOOD, 2020, 136
  • [9] Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin
    Popat, Rakesh
    Badros, Ashraf Z.
    Kumar, Shaji
    Rodríguez-Otero, Paula
    Cohen, Adam D.
    Manier, Salomon
    Voorhees, Peter M.
    Gay, Francesca
    Rifkin, Robert M.
    Martin, Thomas
    Chari, Ajai
    Weisel, Katja
    Farooq, Asim V.
    Jeng, Bennie H.
    Chng, Wee Joo
    Lee, Hans C.
    Berdeja, Jesus
    Jadhav, Vinay
    Tosolini, Alessandra
    Eliason, Laurie
    Palumbo, Antonio
    Dimopoulos, Meletios A.
    Lonial, Sagar
    Trudel, Suzanne
    Richardson, Paul G.
    Terpos, Evangelos
    BLOOD, 2021, 138
  • [10] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment
    Kortuem, M.
    Lee, H. C.
    Cohen, A. D.
    Chari, A.
    Hultcrantz, M.
    Nooka, A. K.
    Callander, N.
    Suvannasankha, A.
    Badros, A.
    Libby, E.
    Trudel, S.
    Richardson, P.
    Sborov, D.
    Rodriguez Otero, P.
    Lonial, S.
    Zhi, E.
    Lewis, E.
    Gupta, I
    Opalinska, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 102 - 102
12345